Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Cabergoline

3

V.c Pleural thickening - Fibrothorax

2
Last update : 10/07/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Pleuropulmonary Toxicity of Another Anti-Parkinson's Drug: Cabergoline.
The open respiratory medicine journal 2009 Jun 05;3;90-3 2009 Jun 05
Pleural effusion and thickening due to cabergoline use in a patient with Parkinson's disease.
European journal of internal medicine 2005 Apr;16;129-131 2005 Apr
Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
Heart (British Cardiac Society) 2004 Aug;90;e47 2004 Aug
Fibrosis associated with dopamine agonist therapy in Parkinson's disease.
Clinical neuropharmacology 2003;26;109-11 2003
Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
Mayo Clinic proceedings 1999 Apr;74;371-5 1999 Apr
Pleuropulmonary changes induced by ergoline drugs.
The European respiratory journal 1996 May;9;1013-9 1996 May
Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
Archives of internal medicine 1988 Oct;148;2231-6 1988 Oct

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies